Addition Therapeutics
PrivateLast Round
Series A
Extension
Dec 22, 2025
Total Funding Raised
$106M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Addition Therapeutics operates in Healthcare & Life Sciences and is based in South San Francisco, California. Its latest recorded funding round was a Series A Extension round in December 2025.
Addition Therapeutics is a biotechnology company developing a new class of genomic medicines using its all-RNA, non-viral, LNP-based PRINT (Precise RNA-Mediated Insertion of Transgenes) platform to create one-time therapies for chronic and rare diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Addition Therapeutics Comparables
Compare Addition Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Fractyl Health | 77% | |
| Remedium Bio | 77% | |
| Amgen | 67% |
For institutional investors. Book with your work email.
Addition Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Dec 22, 2025 | ||||
| Series A | Sep 1, 2023 |
For institutional investors. Book with your work email.
Addition Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| BEVC | Series A, Series A Extension |
| Gates Family Foundation | Series A Extension |
| Osage University Partners | Series A, Series A Extension |
| Gates Foundation | Series A Extension |
| Abingworth | Series A, Series A Extension |
| Bill & Melinda Gates Foundation | Series A, Series A Extension |
| Pivotal bioVenture Partners | Series A, Seed, Series A Extension |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 27, 2026
Developing a gene therapy for permanent GLP-1 production in liver cells.
- Dec 22, 2025
$100M Series A round completed.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventOct 27, 2026
Addition Therapeutics, Inc. presents new preclinical data from its PRINT(TM) programs, including an oral presentation on the PRINT platform and posters on Fabry disease and hypothalamic obesity, at the European Society of Gene & Cell Therapy's 33rd Annual Congress in Hamburg, Germany, in Oct '26.
- attends_eventOct 27, 2026
Addition Therapeutics, Inc. attends ESGCT 2026 in Germany from Oct 27th-30th '26 and plans to present new preclinical data on its Fabry disease and hypothalamic obesity programs and its PRINT platform.
For institutional investors. Book with your work email.
Addition Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Addition Therapeutics's valuation, stock price, and market status.
Is Addition Therapeutics a public or private company?
Addition Therapeutics is a private company.
What is the current stock price of Addition Therapeutics?
Addition Therapeutics is a private company, so its shares have no public market price. Caplight tracks Addition Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Addition Therapeutics worth (valuation)?
Valuation information for Addition Therapeutics is not publicly available.
Can I buy Addition Therapeutics stock?
Addition Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Addition Therapeutics's last funding round?
Addition Therapeutics's most recent funding round was Series A Extension on December 22, 2025.
Who are the main investors in Addition Therapeutics?
Key investors in Addition Therapeutics include Pivotal bioVenture Partners, SR One.
Will Addition Therapeutics IPO soon?
No public IPO plans have been announced for Addition Therapeutics.
How can I track Addition Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Addition Therapeutics's shares on secondary markets.